6 VARIATION IN PRACTICE IN ENDOMETRIAL CANCER (EC): CAN MOLECULAR CLASSIFICATION DIRECT CARE AND REDUCE COSTS ASSOCIATED WITH MANAGEMENT?

1E Thompson, 1A Lum, 1H Xu, 2S Scott, 1L Yu, 1E He, 1T Salisbury, 1S Keane, 1S Keane, 1V Samouelian, 1J Irving, 1S Salvador, 1L Helpman, 1C Wolhmuth, 1M Kinloch, 1S Offman, 1D Vivas, 1K Grondin, 1W Giteb, 1M Plante, 1H Huntsman, 1A Tallhouk, 1CB Gilks, 1G Hanley, 1M Alpina.

1University of British Columbia and BC Cancer, Canada; 2Genetic Pathology Evaluation Center, Canada; 3Dalhousie University Medical School, Canada; 4Centre hospitalier de l’Université de Montréal, Canada; 5McGill University, Canada; 6McMaster University and the Juravinski Cancer Centre, Canada; 7Sunnybrook Health Sciences Center, Canada; 8University of Saskatchewan, Canada; 9Université Laval, Canada

10.1136/ijgc-2020-IGCS.6

Objectives We wished to assess the potential impact of directing EC management based on molecular classification, and the projected cost implications of molecular subtype-directed care.

Methods Surgical staging, treatment, surveillance, and hereditary cancer program (HCP) referrals were assessed for all ECs managed in a single calendar year (2016) across 24 Canadian centers. Variation of practice was recorded, as well as where a change in management would be projected and associated cost implications of that change based on molecular subtype assignment.

Results Data from 862 patients revealed wide variation in surgical staging, with lymph node dissection (LND) performed in 61% of ECs (range 25–100%), including 38% LND in GrI ECs (0–100%). Adjuvant therapy (type, when/ if given) and cancer surveillance (frequency, site e.g., community vs. cancer center) was inconsistent within and across centers for both early- and late-stage disease. Molecular classification identified 29% MMRd ECs (n=247) but only 8% of these women had been referred to HCP. 30 women who did consult HCP were MMRproficient. 38% of MMRd ECs had no LND and 43% did not receive radiation. 16% and 18% of p53abn ECs had no LND or omentectomy respectively, and only 58% received chemotherapy. De-escalation of treatment in early-stage POLEmut and NSMP ECs (n=63 treated, where molecular classification would direct observation or brachytherapy-only) would have reduced costs by $348,896–407,830 CAD or $5338–6466 CAD per patient.

Conclusions There is currently profound variation in practice for all aspects of EC management with implications to patients and health systems. Molecular classification can provide consistency in care and directly biologically-informed management.

7 SENTINEL LYMPH NODE BIOPSY VERSUS LYMPHADENECTOMY FOR INTERMEDIATE AND HIGH GRADE ENDOMETRIAL CANCER STAGING (SENTOR TRIAL): A PROSPECTIVE MULTICENTER COHORT STUDY

1M Cusimano, 1D Vicas, 1K Pulman, 1MO Bernardini, 1G Bouchard-Fortier, 1S Laframboise, 1T May, 1L Hogen, 1A Covens, 1LT Gien, 1R Kupets, 1M Rouzbahman, 1BA Clarke, 1M Mitrovis, 1M Cesari, 1C Turashvil, 1M Maganti, 1A Zia, 1GEV Ene, 1S Ferguson, 1University of Toronto, Canada; 2Sunnybrook Health Sciences Centre, Canada; 3Tollum Health Partners, Canada; 4University Health Network, Canada; 5Sinai Health Systems, Canada

10.1136/ijgc-2020-IGCS.7

Background It is unclear whether sentinel lymph node biopsy (SLNB) can replace lymphadenectomy in women with high grade endometrial cancer (EC). We performed a prospective multicenter cohort study (the SENTOR trial) to evaluate the diagnostic accuracy of SLNB using indocyanine green in intermediate and high grade EC (NCT01886066).

Methods Patients with clinical stage I grade 2 endometroid or high grade EC scheduled for minimally invasive hysterectomy at three academic centers in Toronto, Canada, were prospectively enrolled for SLNB followed by pelvic (PLND) and paraaortic lymphadenectomy (PALND) as the reference standard. The study was powered to determine sensitivity of the SLNB algorithm as the primary endpoint.

Results We enrolled 156 patients (126 high grade); all underwent SLNB and PLND, and 106 (84%) with high grade EC underwent PALND. Sentinel lymph node detection rates were 97% per patient (95% CI 94–99), 88% per hemipelvis (95% CI 83–91), and 78% bilaterally (95% CI 70–84). Of 27 patients (17%) with nodal metastases, 26 were correctly identified by the SLNB algorithm, yielding a sensitivity of 96% (95% CI 81–100), false negative rate of 4% (95% CI 0–19), and negative predictive value of 99% (95% CI 96–100). Only one patient (0.6%) was misclassified by the SLNB algorithm. Two of 27 node-positive patients (7.5%) were identified outside traditional PLND boundaries, and five of 27 (18.5%) required immunohistochemistry for diagnosis.

Conclusion SLNB has comparable, if not superior, diagnostic accuracy relative to lymphadenectomy in high grade EC patients. SLNB is a viable option for the surgical staging of EC.

8 A MULTICENTRIC RANDOMIZED TRIAL TO EVALUATE THE ROLE OF UTERINE MANIPULATORS ON LAPAROSCOPIC/ROBOTIC HYSTERECTOMY FOR THE TREATMENT OF LOW-RISK ENDOMETRIAL CANCER: THE ROMANHY TRIAL (NCT:02762214)

1G Guelli Allotti, 1E Perone, 1C Fedele, 1G Vizielli, 1A Fagotti, 1V Gallotta, 1C Rossitto, 1B Costantini, 1S Restaino, 1G Montessori, 1F Fanfani, 1G Scambia, 1S Cianci, 1V Chiartano, 1S Uccella, 1A Ercoli. 1Division of Gynecologic Oncology, Fondazione Polyclinico Universitario A. Gemelli IRCCS, Italy; 2Department of Woman, Child and General and Specialized Surgery, University of Campania ‘Luigi Vanvitelli’, Italy; 3Department of Gynecologic Oncology, ARNAS Civico Di Cristina Benfratelli, Università di Palermo, Italy; 4Department of Obstetrics and Gynecology, AOUI Verona, Università di Verona, Italy; 5Division of Obstetrics and Gynecology, Università degli studi di Messina, Policlínico G. Martino, Italy

10.1136/ijgc-2020-IGCS.8

Background The role of the intrauterine manipulator in minimally invasive hysterectomy for endometrial cancer has been widely debated in terms of impact on the oncological outcomes. To date, definitive conclusions on the possible advantages and oncological safety of its use in endometrial cancer staging are still awaited.

Objectives This randomized trial aimed to assess the role of the uterine manipulator in terms of oncological and perioperative outcomes in patients undergoing minimally invasive (laparoscopic/robotic) staging for presumed low-risk endometrial cancer.